Title: Excess Mortality probably due to COVID-19 in Tokyo, Japan between August and
 October, 2020

Junko Kurita[1]*,Tamie Sugawara[2], Yoshiyuki Sugishita[2], Yasushi Ohkusa[2]

1 Department of Nursing, Tokiwa University, Ibaraki, Japan

[2] Infectious Disease Surveillance Center, National Institute of Infectious Diseases,

 Shinjuku, Tokyo, Japan

Keywords: excess mortality; COVID-19; all cause death; stochastic frontier estimation;

NIID model; Tokyo; Japan

*) Correspondence to:

Corresponding author: Junko Kurita, kuritaj@tokiwa.ac.jp

Abstract

Background: As of March, 2021, the COVID-19 outbreak has been record the highest peak in the end of December, 2020. Nevertheless, no remarkable excess mortality attributable to COVID-19 has been observed.

Object: We sought to quantify excess mortality in April using the National Institute of Infectious Diseases (NIID) model.

Method: We applied the NIID model to deaths of all causes from 1987 up through January, 2021 for the whole of Japan and up through October for Tokyo.

Results: Results in Japan show very few excess mortality in August and October, 2020 It was estimated as 12 and 104. Conversely, in Tokyo, 595 excess mortality was detected between August and Octoember, which was 3.1% and 1.7% of baseline.

Discussion and Conclusion: We detected substantial excess mortality in Tokyo but a few in Japan. It might be important to continue to monitor excess mortality of COVID-19 carefully hereafter.

1. Introduction

To date, excess mortality has mainly been used to assess the social effects of influenza activity [1–6]. However, since the emergence of COVID-19, excess mortality attributable to COVID-19 has been attracting attention [7] as a measure of the total effects of the disease because it can reflect cases which have not been identified as polymerase chain reaction (PCR) positive. Especially in Japan, PCR tests administered per capita have been few. Therefore, concern has arisen about the possibility that some deaths caused by COVID-19 have not been recognized heretofore. Moreover, excess mortality related to COVID-19 might be expected to contribute to evaluation of vaccine effects. For these evaluations, the estimated excess mortality without the effects of a vaccine should be regarded as a baseline. Nevertheless, no such a trial has been undertaken to date. This study might be the first trial to measure that figure in Japan.

As of the end of Janary, 2021, the COVID-19 outbreak showed its highest peak on April 3. In all, about 17 thousand patients and about one thousand deaths from the outbreak have been reported in Japan. Although Japan has about one third of the population of the U.S., these figures are vastly different in scale from those of the U.S., which has reported 1.93 million cases of morbidity and 110 thousand cases of mortality (deaths) [8]. In light of the much lower number of patients in Japan, some criticism has arisen that low PCR testing rates might have led to the lower number of documented patients [9]. In this sense, one might regard the number of deaths as reflecting the actual situation in Japan, but with no testing-related bias.

Concerning deaths, the case-fatality rate (CFR) is about 5%. In fact, the CFRs in both countries are not much different. The lower PCR testing in Japan might be related to some problems. Therefore, we specifically examined excess mortality attributable to

COVID-19 in Japan, irrespective of the cause of death.

In Japan, excess mortality was estimated using the National Institute of Infectious Diseases (NIID) model [10], which has been the official procedure for more than ten years. It was applied to two data sources: the national monthly deaths of all causes and the respective weekly pneumonia and influenza deaths in the 21 largest cities and their total. The latter is published regularly in Japanese during the influenza season as https://www.niid.go.jp/niid/ja/flu-m/2112-idsc/jinsoku/131-flu-jinsoku.html. Unfortunately, that publication ceased in March 2020 because it is intended for influenza. The first peak in Japan was April 3[11]: excess mortality cannot be detected until March. Instead, we applied NIID model to the all causes of death in April to Decmber, 2020 in the whole of Japan.

2. Method

Excess mortality is defined as the difference between the actual number of deaths and an epidemiological threshold. The epidemiological threshold is defined as the upper bound of the 95% confidence interval (CI) of the baseline. The baseline is defined as the number of deaths that are likely to have occurred if an influenza outbreak had not occurred. Therefore, if the actual deaths are fewer than the epidemiological threshold, then excess mortality is not inferred.

The data used for this study were monthly deaths of all causes from 1987 through January 2021[12]. NIID model, the Stochastic Frontier Estimation [13–19], is presented

as

$$log\ D_t=\alpha+\beta T_t+\gamma T_t^2+\Sigma\eta_i M_{it}+\varepsilon_t \quad and \qquad\qquad (1)$$

$$\varepsilon_{t=}v_t+|\omega_t|\ , \qquad\qquad (2)$$

where D_t represents all causes of death in month/year t, T_t denotes the linear time trend,

and M_{it} is the dummy variable for a month, which is one if t is the i-th month and

otherwise zero. Moreover, v_t and ω_t are stochastic variables as $v_t \sim N(0,\ \mu^2)$ and ω_t

$\sim N(0,\xi^2)$; they are mutually independent. Although v_t represents stochastic disturbances,

ω_t denotes non-negative deaths attributable to influenza. These disturbance terms in this

model are parameterized by two parameters: ξ/μ and $(\mu^2+\xi^2)^{0.5}$. If the null hypothesis

$\xi/\mu=0$ is not rejected, then the Stochastic Frontier Estimation model is inappropriate.

Study areas were the whole of Japan and its capital, Tokyo. Study period foe

estimation was from 1987 to January 2021 for the whole of Japan and up through

October for Tokyo. We adopted 5% as significant level.

3. Results

Table 1 summarized the estimation results in the whole of Japan and Table 2 for

Tokyo. Figure 1 presents observed deaths, the estimated baseline, and its threshold in

Japan. Figure 2 specifically depicts the last year in Japan. We found 12 and 104

excess mortality in August and October, 2020

Figure 3 and 4 showed the estimated result in Tokyo. We found 595 excess mortality in

August and 150 excess mortality in September and 76 in Octobe, which was 3.1, 1.7

and 0.8% of the baseline.

4. Discussion

This study applied the NIID model to all causes of death to detect excess mortality

attributable to COVID-19. We found 12 and 104 excess mortality in August and

October, 2020.

Moreover, we found 671 excess mortality between August and October r in Tokyo

which correspondences to approximately 3.1, 1.7 and 0.8% of the baseline. It may not

be a few excess mortality. It might be increasing after September, especially in winter,

even though excess mortality in the whole of Japan were very few at least until January,

2021.

On the other hand, about 5800 mortality cases caused by COVID-19 confirmed by

PCR testing, were reported in MHLW officially as of January, 2021 throughout Japan

[12]. Therefore, even if COVID-19 actually caused external mortality, neither the NIID

model nor another statistical model might would detect significant effects attributable to

COVID-19. Of course, some deaths from COVID-19 might not have been tested and

might have been excluded from these official numbers of mortality cases. However, total deaths might include deaths without diagnosis as COVID-19, but actually those associated with COVID-19. Estimation results suggest that such unrecognized deaths associated with COVID-19 are not significant, even if they exist.

Some researchers in Japan have emphasized considerable excess mortality from all causes of death through October of around 19 thousand at maximum due to COVID-19 [20] when using the Farrington algorithm [21] and EuroMOMO [22], which was more than ten times larger than the number of death confirmed by PCR test. This study measured excess mortalities as the gap between observation and beeline, not threshold as, in prefectures where observation was higher than threshold. Therefore, their estimated too huge excess mortality may seriously mislead the risk participation for COVID-19 among the general population.

In particular, in Tokyo, though they found 18 excess mortality in May, we did not found it. It probably suggested that their adopted procedure have upper biased for excess mortality comparison with NIID model, which was suggested logically [23].

Conversely, because we found that the number of total death were lower than baseline in nationwide until July and very few excess mortality in August and October, we might emphasize negative excess mortality which means precaution among people

including wearing masks, washing hand by alcohol, and keep social distance reduce the infection risk of not only for COVID-19 as well as other infection diseases. Therefore, total number of death had decreased offsetting completely the effect of COVID-19.

Using pneumonia death data instead of total death data might be better to evaluate excess mortality caused by COVID-19. However, application rule of the International Classification of Diseases was revised on January 2017, after which pneumonia deaths decreased by approximately 25%. April 2020 was the fourth April since that of 2017. However, excess mortality in pneumonia death should be our next challenge.

5. Conclusion

We found substantial excess mortality since the outbreak of COVID-19 had emerged in Tokyo between August and October. It might be increasing rapidly in winter season. It should be important to continue to monitor excess mortality of COVID-19 carefully hereafter.

The present study is based on the authors' opinions: it does not reflect any stance or policy of their professionally affiliated bodies.

6. Acknowledgement

We acknowledge Dr. Nobuhiko Okabe, Kawasaki City Institute for Public Health, Dr.Kiyosu Taniguchi, National Hospital Organization Mie National Hospital, and

Dr.Nahoko Shindo, WHO for their helpful support.

7. Conflict of interest

The authors have no conflict of interest to declare.

8. Ethical considerations

All information used for this study was published on the web site of MHLW [12].

Therefore, no ethical issue is presented.

9. References

1)   Lin HC, Chiu HF, Ho SC, Yang CY. Association of influenza vaccination and

      reduced risk of stroke hospitalization among the elderly: a population-based

      case-control study. Int J Environ Res Public Health 2014; 11: 3639-49.

2)   Asghar Z, Coupland C, Siriwardena N. Influenza vaccination and risk of stroke:

      Self-controlled case-series study. Vaccine. 2015; 33: 5458-63.

3)   Riedmann EM. Influenza vaccination reduces risk of heart attack and stroke. Hum

      Vaccin Immunother 2013; 9: 2500.

4)   Kwok CS, Aslam S, Kontopantelis E, Myint PK, Zaman MJ, Buchan I, Loke YK,

      Mamas MA. Influenza, influenza-like symptoms and their association with

cardiovascular risks: a systematic review and meta-analysis of observational

studies. Int J Clin Pract. 2015;69:928-37.

5)   Muhammad S, Haasbach E, Kotchourko M, Strigli A, Krenz A, Ridder DA, Vogel

AB, Marti HH, Al-Abed Y, Planz O, Schwaninger M. Influenza virus infection

aggravates stroke outcome. Stroke. 201142 783-91.

6)   Assad F, Cockburn WC, Sundaresan TK. Use of excess mortality from respiratory

diseases in the study of influenza. Bull WHO 1973; 49: 219-33.

7)   US Center for Disease Control and Prevention. Excess Deaths Associated with

COVID-19. https://www.cdc.gov/nchs/nvss/vsrr/covid19/excess_deaths.htm

[accessed on July 15, 2020]

8)   Japan   Times.   Japan's   daily   PCR   test   capacity   tops   20,000.

https://www.japantimes.co.jp/news/2020/05/16/national/japans-daily-pcr-test-capa

city-20000/#.XuAwImeP6AA [accessed on July 10, 2020]

9)   World Health Organization. Coronavirus disease (COVID-2019) situation reports.

https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-repor

ts/ [accessed on January 22,2021]

10) Sugawara T, Ohkusa Y. Comparison of Models for Excess Mortality of Influenza

Applied to Japan. Journal of Biosciences and Medicines, 2019, 7, 13-23.

doi:10.4236/jbm.2019.76002

11) Kurita J, Sugawara T, Ohkusa Y. Mobility data can explain the entire COVID-19 outbreak course in Japan. medRxiv 2020.04.26.20081315; doi: https://doi.org/10.1101/2020.04.26.20081315

12) Ministry of Health, Labour and Welfare. Preliminary statistics on demographicshttps://www.mhlw.go.jp/toukei/list/81-1a.html (in Japanese) [accessed on July 26, 2020]

13) Aiger AD, Lovell K, Schmitidt P. Formulation and estimation of stochastic frontier production function models. Journal of Econometrics 1977; 21-37.

14) Jondrow J, Lovell K, Materov S, Schmidt P. On the estimation of technical inefficiency in the stochastic frontier production function model. Journal of Econometrics 1982; 233-9.

15) Li T, Rosenman R. Cost inefficiency in Washington Hospitals: A stochastic frontier approach using panel data, Health Care Management Science 2001; 4: 73-81.

16) Newhouse JP. Frontier Estimation: How useful a tool for health economics? Journal of Health Economics 1994; 13: 317-22.

17) Shelton Brown H. Managed care and technical efficiency. Health Economics.

2003; 12: 149-58.

18) Jacobs R. Alternative methods to examine hospital efficiency: Data envelopment

analysis and stochastic frontier analysis. Health Care Management Science. 2001;

4: 103-15

19) Rosko MD. Cost efficiency of US hospitals: A stochastic frontier approach.

Health Economics. 2001; 539-51.

20) National Institute of Infectious Diseases, Excess mortality in Japan, on October

2020.

https://www.niid.go.jp/niid/ja/from-idsc/493-guidelines/10150-excess-mortality-2

1jan.html (in Japanese) [accessed on February 5, 2021]

21) Center of Disease Control and Prevention, Excess Deaths Associated with

COVID-19https://data.cdc.gov/NCHS/Excess-Deaths-Associated-with-COVID-19

/xkkf-xrst [accessed on September 7, 2020]

22) EUROMOMO,EUROMOMO, https://www.euromomo.eu/ [accessed on

September 7, 2020]

23) Sugawara T, Ohkusa Y. Comparison of Models for Excess Mortality of Influenza

Applied to Japan. Journal of Biosciences and Medicines, 2019, 7, 13-23.

doi:10.4236/jbm.2019.76002

Table 1 NIID Model estimation results since 1987 until January 2021 in Japan

Explanatory variables	Estimated coefficients	p-value
Constant	11.12	<0.0004
Time trend	0.001537	<0.0004
Time trend ^{2}	0.0000009763	0.423
January	0.07075	<0.0004
February	-0.05631	<0.0004
March	-0.01671	0.053
April	-0.1027	<0.0004
May	-0.1247	<0.0004
June	-0.2126	<0.0004
July	-0.1776	<0.0004
August	-0.1710	<0.0004
September	-0.2083	<0.0004
October	-0.1197	<0.0004
November	-0.08768	<0.0004
ζ/μ	2.386	<0.0004
$(\mu^2+\zeta^2)^{0.5}$	0.04934	<0.0004

Note: For the 404 observations, the log likelihood was 899.957. ζ^2 denotes the variance of the non-negative disturbance term. μ^2 is the variance of the disturbance term.

Table 2 NIID Model estimation results since 1987 until September 2020 in Tokyo

Explanatory variables	Estimated coefficients	*p*-value
Constant	8.55	<0.0004
Time trend	0.00186	<0.0004
Time trend ^{2}	$-0.726*10^{-6}$	0.001
January	0.0759	<0.0004
February	0.137	<0.0004
March	0.0292	0.015
April	0.0479	<0.0004
May	-0.0271	0.111
June	-0.0584	<0.0004
July	-0.111	<0.0004
August	-0.0664	<0.0004
September	-0.0719	<0.0004
October	-0.108	<0.0004
November	-0.0253	0.102
ξ/μ	2.44	<0.0004
$(\mu^2+\xi^2)^{0.5}$	0.0 684	<0.0004

Note: For the 402 observations, the log likelihood was 771. ξ^2 denotes the variance of the non-negative disturbance term. μ^2 is the variance of the disturbance term.

Figure 1: Observations of the estimated baseline and threshold since 1987 until
January 2021 in Japan

(persons)

Month/Year

Note: The blue line represents observations. The orange line represents the estimated
baseline. The gray line shows its threshold.

Figure 2: Observation of the estimated baseline and threshold sinceJanuary 2020 in Japan

(persons)

Month/Year

Note: The blue line represents observations. The orange line represents the estimated baseline. The gray line shows its threshold.

Figure 3: Observations of the estimated baseline and threshold since 1987 until October
2020 in Tokyo

(persons)

Note: The blue line represents observations. The orange line represents the estimated
baseline. The gray line shows its threshold.

Figure 4: Observation of the estimated baseline and threshold since May 2019 until
October 2020 in Tokyo

(persons)

Note: The blue line represents observations. The orange line represents the estimated
baseline. The gray line shows its threshold.